These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36086755)

  • 1. Effectiveness and safety of electroacupuncture and its cotreatment with electronic moxibustion in the treatment of patients with moderate benign prostatic hyperplasia using alpha blocker: An assessor-blinded, randomized, controlled pilot study.
    Kim HB; Han CH; Jeon JH; Kim E; Kwon O; Choi YE; Yang C; Park YC; Kim YI
    Medicine (Baltimore); 2022 Sep; 101(36):e30386. PubMed ID: 36086755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of electroacupuncture and its cotreatment with electronic moxibustion in the treatment of patients with moderate benign prostatic hyperplasia using alpha blocker: Study protocol for an assessor-blinded, randomized controlled clinical trial.
    Kim HB; Kim YI; Jeon JH; Kim E; Kim JY; Kwon O; Choi YE; Yang C; Han CH
    Medicine (Baltimore); 2020 Apr; 99(15):e19678. PubMed ID: 32282720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxibustion as an adjunct for lower urinary tract symptoms associated with benign prostate enlargement: A randomized controlled pilot trial.
    Lee HY; Bae GE; Lee SD; Nam JK; Yun YJ; Han JY; Lee DH; Choi JY; Park SH; Kwon JN
    Medicine (Baltimore); 2020 Jan; 99(4):e18918. PubMed ID: 31977907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
    BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD010060. PubMed ID: 30480763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The results of the multicenter prospective comparative study of Androgel in men with endogenous testosterone deficiency and lower urinary tract symptoms, associated with benign prostate hyperplasia (POTOK)].
    Kogan MI; Avadieva NE; Gevorkyan LS; Loginov YA; Metelkin AM; Mitin AA; Patrikeev AA
    Urologiia; 2023 May; (2):32-40. PubMed ID: 37401702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a protocol for a parallel-group, randomised, controlled pilot trial.
    Lee HY; Nam JK; Lee SD; Lee DH; Han JY; Yun YJ; Lee JH; Park HL; Park SH; Kwon JN
    BMJ Open; 2015 Dec; 5(12):e008338. PubMed ID: 26656981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Viktrup L; Hayes RP; Wang P; Shen W
    BMC Urol; 2012 Nov; 12():30. PubMed ID: 23134716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized, open-label, parallel trial comparing the efficacy of α-blocker or 5α-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Lee KS; Yoo JW; Kim DH; Jeon S; Yang J; Chung BH; Koo KC
    Prostate; 2024 Mar; 84(4):403-413. PubMed ID: 38149792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microwave thermotherapy for benign prostatic hyperplasia.
    Hoffman RM; Monga M; Elliott SP; Macdonald R; Langsjoen J; Tacklind J; Wilt TJ
    Cochrane Database Syst Rev; 2012 Sep; (9):CD004135. PubMed ID: 22972068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
    Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J
    Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Garimella PS; Fink HA; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electroacupuncture for moderate and severe benign prostatic hyperplasia: a randomized controlled trial.
    Wang Y; Liu B; Yu J; Wu J; Wang J; Liu Z
    PLoS One; 2013; 8(4):e59449. PubMed ID: 23593139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
    Porst H; Oelke M; Goldfischer ER; Cox D; Watts S; Dey D; Viktrup L
    Urology; 2013 Sep; 82(3):667-73. PubMed ID: 23876588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms.
    Cho S; Kwon SS; Lee KW; Yoo TK; Shin DG; Kim SW; Bae JH; Choi H; Kim YH
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28508455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
    World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis.
    Kim HJ; Sun HY; Choi H; Park JY; Bae JH; Doo SW; Yang WJ; Song YS; Ko YM; Kim JH
    PLoS One; 2017; 12(1):e0169248. PubMed ID: 28072862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.